Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease
Clinical Pharmacology & Therapeutics · 2024
DOI: 10.1002/cpt.3342 ↗Kurz gefasst
Randomisierte kontrollierte Studie in der Zeitschrift Clinical Pharmacology & Therapeutics, 2024. Verfasst von Pamela Navarro-Gonzales und 4 weiteren Autor:innen. Beteiligte Einrichtung: Akebia Therapeutics, Inc., Cambridge, Massachusetts, USA. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Healthy Volunteers, Glycine. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Vadadustat is an oral hypoxia‐inducible factor prolyl hydroxylase inhibitor for treating anemia in chronic kidney disease (CKD). Single ascending dose (SAD) and multiple ascending dose (MAD) studies assessed pharmacokinetics (PK), pharmacodynamics (PD), and safety of vadadustat in healthy volunteers. A single‐dose, open‐label study was conducted in patients with CKD stages 3 and 4 not on dialysis. In the SAD study, 48 healthy adult men ( n = 8/cohort) received single doses of vadadustat (80–1,200 mg) or placebo. In the MAD study, 34 healthy adult men ( n = 8–9/cohort) received daily vadadustat (500–900 mg) or placebo for 10 days. In the single‐dose CKD study, 22 male and female patients with CKD (stage 3: n = 10; stage 4: n = 12) received single doses of vadadustat (500 mg). PK parameters included plasma vadadustat; PD biomarkers were measured, including erythropoietin (EPO) levels, reticulocytes, and others. Plasma vadadustat peaked 3–4 hours after single or multiple dosing in healthy volunteers, with a mean t 1/2 of approximately 4.5 hours. In patients with CKD, plasma vadadustat peaked at 5–6 hours, with a mean t 1/2 of 7.2 (stage 3) and 8.5 (stage 4) hours. Vadadustat AUC ∞ and C max increased dose proportionally in SAD and MAD trials. In all trials, EPO concentrations increased in a dose‐related manner and returned approximately to baseline by 24 hours. Adverse events were mild and considered not study drug related. The PK and PD results of these studies were utilized for further clinical development of vadadustat for treatment of anemia in CKD patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Akebia Therapeutics, Inc., Cambridge, Massachusetts, USA.
- Department of Medicine and Pathology, David Geffen School of Medicine, University of California Los Angeles, Los Angeles, California, USA.
- Renal Associates, PA, San Antonio, Texas, USA.
ORCID-Profile: Pamela Navarro-Gonzales, Tomas Ganz, Pablo E Pergola, Anna Zuk, Kevin Dykstra
Zitieren
APA
Navarro-Gonzales, P., Ganz, T., Pergola, P. E., Zuk, A., & Dykstra, K. (2024). Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease. Clinical Pharmacology & Therapeutics. https://doi.org/10.1002/cpt.3342
Vancouver
Navarro-Gonzales P, Ganz T, Pergola PE, Zuk A, Dykstra K. Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease. Clinical Pharmacology & Therapeutics. 2024. doi:10.1002/cpt.3342
BibTeX
@article{NavarroGonzales2024,
author = {Navarro-Gonzales, Pamela and Ganz, Tomas and Pergola, Pablo E and Zuk, Anna and Dykstra, Kevin},
title = {Pharmacokinetics, Pharmacodynamics, and Safety of Vadadustat in Healthy Volunteers and Patients with Chronic Kidney Disease},
journal = {Clinical Pharmacology & Therapeutics},
year = {2024},
doi = {10.1002/cpt.3342}
}
EUVIMED